Non-alcoholic fatty liver disease articles from across Nature Portfolio

This study characterizes expression of pharmacogenes across the histological NAFLD severity spectrum. Here, the authors show the downregulation of CYP2C19 in NAFLD which supports developing personalized medicine approaches for drugs sensitive to metabolism by the CYP2C19 enzyme.

Bacterial nicotinamidase/pyrazinamidase PncA increases host nicotinamide adenine dinucleotide (NAD⁺) levels and ameliorates diet-induced non-alcoholic fatty liver disease (NAFLD) in mice.

This Consensus Statement discusses the relationship between hyperferritinaemia and iron accumulation in individuals with metabolic dysfunction. The authors propose an updated definition and a provisional staging system for metabolic hyperferritinaemia, highlight research gaps and provide suggestions for the design and outcome measures for future studies.